alexa [Mucolytic and antioxidant agents for exacerbations of chronic obstructive pulmonary disease: A meta-analysis].


Journal of Lung Diseases & Treatment

Author(s): Li X, Sun H, Liu C, Kang J

Abstract Share this page

Abstract OBJECTIVE: To assess the effects and safety of long-term oral mucolytic and antioxidant agents for exacerbations in patients with stable chronic obstructive pulmonary disease. And to further discuss the drug dose and concomitant ICS on the effects. METHODS: Systematic searches were performed in Medline and Google Scholar databases. Randomized controlled trials which compared regular oral mucolytic and antioxidant agents with placebo and reported exacerbations over a treatment period more than 3 months were selected. Stata version 11 was used for data analysis. RESULTS: Ten RCTs involving 3 434 patients were identified. Compared with placebo, the use of mucolytic and antioxidant agents was associated with a reduction of 0.36 exacerbations per patient per year (95\%CI 0.47 to 0.26). The subgroup analysis restricting to studies without concomitant ICS indicated that there was a larger decrease between the two groups (WMD=-0.58, 95\% CI -0.89--0.27). The analysis of NAC dose on the effect indicated that high-dose NAC treatment could significantly reduce the exacerbations (WMD=-0.39, 95\% CI -0.61--0.16, z=3.33, P=0.001). While in the low-dose NAC group, only those studies with low rate of concomitant ICS showed the effects (WMD=-1.25, 95\% CI -1.99--0.51, z=3.32, P=0.001), the difference was not significant in studies with high rate of concomitant ICS (WMD=-0.06, 95\% CI -0.29--0.17, z=0.5, P=0.617). There was no difference in FEV1 improvement (SMD=0.03, 95\%CI -0.09~0.15, z=0.49, P=0.626), but FEF 25\%-75\% showed a significant improvement (SMD=0.41, 95\% CI 0.13-0.68, z=2.90, P=0.004). CONCLUSION: The use of mucolytic and antioxidant agents is associated with a reduction in the number of exacerbations. The effects may be larger in those patients without concomitant ICS. High-dose NAC treatment may be more effective than low-dose group, while the latter may be effective only when the rate of concomitant ICS was low.
This article was published in Zhonghua Jie He He Hu Xi Za Zhi and referenced in Journal of Lung Diseases & Treatment

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version